Resource Center › Case Studies
Ensuring Accurate HCP Data Within Salesforce
Best practices for license validation directly within Salesforce to support Prescription Drug Marketing Act (PDMA)-compliant sample distribution.
Mid-size pharmaceutical manufacturer
DirectID Salesforce, MedProID
Salesforce
PDMA-compliant sampling
The Challenge
A mid-size pharmaceutical manufacturer was managing Healthcare Professional (HCP) state license verification within Salesforce through manual workflows, creating operational delays and bottlenecks for their sales team. Tracking newly licensed practitioners, interpreting varying state regulations and keeping validated data current across thousands of records was a growing burden that limited the field team’s ability to engage compliantly with HCPs.
The Result
By integrating MedProID® data directly into Salesforce, the manufacturer automated both ad-hoc HCP lookups and scheduled batch updates, giving sales representatives validated, current HCP records at the point of engagement. The result was a scalable, Prescription Drug Marketing Act (PDMA)-compliant process that reduced manual effort across the sales operations team and improved data accuracy across the field.
Inside the Full Story
Get the Full Story
The Solutions in This Story
Related resources
-
Provider Verification Beyond Compounding Pharmacy Onboarding
How current provider and facility information supports documented decisions from account setup through order fulfillment.
-
Where Prescriber Verification Fits in the Specialty Pharmacy Workflow
A practical look at verification checkpoints from prescription intake through dispensing and the value of current provider data at each stage.
-
7 Workflow Gaps That Slow Down Life Sciences Compliance Teams
As compliance responsibilities grow, small gaps between data, systems and teams can create extra manual work. Here are 7 places to look first and practical steps your team can take to strengthen the workflow.
-
Two International Disclosure Dates to Plan For
Colombia’s biannual value-transfer filing is due September 30, and Japan’s annual disclosure window follows each company’s fiscal year end.



